Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc.（KYTX）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · KYTX · 截至 2025年9月30日
股东结构概览
79
机构持有人数
▼ 2 vs Q2
$136.33M
机构持仓总市值
▲ $64.91M vs Q2
43.79M
总流通股
freeFloat 45.28%
22.70M
13F 申报持股数
▼ 511,138 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
KYTX 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
VIDA VENTURES ADVISORS, LLC biological products, (no diagnostic substances) | 4.52M | 10.47% | 10.47% | $27.14B | Nov 3, 2025 | — held |
GILEAD SCIENCES, INC. biological products, (no diagnostic substances) | 4.13M | 9.55% | 9.55% | $24.76B | Nov 13, 2025 | — held |
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC biological products, (no diagnostic substances) | 3.37M | 7.79% | 7.79% | $20.21B | Nov 14, 2025 | — held |
PRICE T ROWE ASSOCIATES INC /MD/ biological products, (no diagnostic substances) | 1.51M | 3.50% | 3.50% | $9.07B | Nov 14, 2025 | ▼ 318.3K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.32M | 3.06% | 3.06% | $7.94B | Nov 7, 2025 | ▲ 9.9K |
INSIGHT HOLDINGS GROUP, LLC biological products, (no diagnostic substances) | 989.1K | 2.29% | 2.29% | $5.93B | Nov 14, 2025 | — held |
FRANKLIN RESOURCES INC biological products, (no diagnostic substances) | 677.6K | 1.57% | 1.57% | $4.07B | Nov 13, 2025 | ▼ 17.4K |
MBB PUBLIC MARKETS I LLC biological products, (no diagnostic substances) | 614.5K | 1.42% | 1.42% | $3.69B | Nov 14, 2025 | — held |
CATALIO CAPITAL MANAGEMENT, LP biological products, (no diagnostic substances) | 586.9K | 1.36% | 1.36% | $3.52B | Nov 14, 2025 | — held |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 551.6K | 1.28% | 1.28% | $3.31B | Nov 14, 2025 | ▲ 99.1K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
17
增持
+767.8K 股5
新建仓
首次建仓18
减持
−1.22M 股0
清仓
完全退出净股数变化（前50家）
450.6K
+767.8K / −1.22M
净新增持仓人
+4
新建 5 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
KYTX 内幕交易记录
数据来源：SEC Form 4
10
买入笔数
1
卖出笔数
10.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
CLARK IAN T director | May 27, 2026 | Award | 5,093 | — | — | 21.7K | Form 4 ↗ |
CLARK IAN T director | May 27, 2026 | Award | 20,582 | $8.59 | $176.8K | 20.6K | Form 4 ↗ |
Cohen Fred E director | May 27, 2026 | Award | 5,093 | — | — | 21.7K | Form 4 ↗ |
Cohen Fred E director | May 27, 2026 | Award | 20,582 | $8.59 | $176.8K | 20.6K | Form 4 ↗ |
SEIDENBERG BETH C director | May 27, 2026 | Award | 5,093 | — | — | 21.7K | Form 4 ↗ |
SEIDENBERG BETH C director | May 27, 2026 | Award | 20,582 | $8.59 | $176.8K | 20.6K | Form 4 ↗ |
Shaw Christi Executive Chairperson | May 27, 2026 | Tax Withhold | 4,194 | $8.59 | $36.0K | 66.7K | Form 4 ↗ |
Aktar Mert director | May 27, 2026 | Award | 5,093 | — | — | 21.7K | Form 4 ↗ |
Aktar Mert director | May 27, 2026 | Award | 20,582 | $8.59 | $176.8K | 20.6K | Form 4 ↗ |
Martini Gregory S. Chief Financial Officer | May 18, 2026 | Award | 325,000 | $8.54 | $2.78M | 325.0K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Kyverna Therapeutics, Inc.（KYTX）主要由机构投资者持有，机构持股比例约为 51.8%。公司内部人员持股约 54.72%，散户及公众持股约占剩余的 0.00%。
Kyverna Therapeutics, Inc. 最大机构股东为 VIDA VENTURES ADVISORS, LLC，截至 September 30, 2025 持有约 4.52 million 股，占总流通股的 10.47%。
目前共有 79 家机构持有 KYTX 股票，合计持仓市值约 $136,330,671，数据来源为最新 SEC 13F 申报。
常见问题
KYTX ownershipKyverna Therapeutics, Inc.（KYTX）主要由机构投资者持有，机构持股约 51.8%。最大股东为 VIDA VENTURES ADVISORS, LLC，持股比例 10.47%。内部人员持股约 54.72%。数据来源 SEC Form 13F，截至 September 30, 2025。